On August 12, NH Investment & Securities researcher Na Gwanjun stated, "Strong domestic sales offset sluggish toxin and filler exports. The toxin's reflective profit effect is expected to continue in the second half of the year. Profit improvement confirmed due to reduced selling and administrative expenses. The supplementary document review in China is in the final stage, with approval expected in Q3 and launch in Q4." He set Hugel's target price at 203,000 KRW.
Over the past five days, individual investors have net sold 65,169 shares of Hugel, while foreigners and institutions have net bought 68,938 shares and net sold 8,188 shares, respectively.

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
